Depression-related central nervous system targets

Depression-related central nervous system (CNS) targets encompass a broad range of proteins and pathways involved in the regulation of mood, emotion, and cognitive function. Historically, the focus has been on the monoamine system, specifically the transporters for serotonin (SERT), norepinephrine (NET), and dopamine (DAT), which are the primary targets for traditional antidepressants like SSRIs and SNRIs (Stahl, 2013, Stahl's Essential Psychopharmacology). Beyond transporters, various G protein-coupled receptors, such as the 5-HT1A and 5-HT2A receptors, are modulated to fine-tune neurotransmission and alleviate depressive symptoms (Artigas, 2013, Pharmacological Reviews). More recently, the glutamatergic system, particularly the N-methyl-D-aspartate (NMDA) receptor, has emerged as a critical target, with drugs like ketamine providing rapid-acting antidepressant effects by promoting synaptic plasticity (Zanos & Gould, 2018, Nature Reviews Drug Discovery). These targets also include components of the hypothalamic-pituitary-adrenal (HPA) axis and neurotrophic factors like brain-derived neurotrophic factor (BDNF), which support neuronal survival and connectivity in brain regions such as the hippocampus (Duman & Monteggia, 2006, Biological Psychiatry). Pharmacological intervention at these sites aims to correct neurochemical imbalances and reverse the structural atrophy associated with chronic stress and depression. However, targeting these complex systems carries risks, including serotonin syndrome, metabolic changes, and the potential for increased suicidality in certain populations (FDA, 2004, Antidepressant Use in Children, Adolescents, and Adults).

Other names

Major depressive disorder targetsMDD targetsAntidepressant targetsCNS targets for depression

The mechanisms involve the inhibition of neurotransmitter reuptake (e.g., SSRIs, SNRIs), antagonism of excitatory receptors (e.g., NMDA antagonists), inhibition of metabolic enzymes (e.g., MAOIs), and direct modulation of post-synaptic receptors to enhance neuroplasticity and monoaminergic signaling.